The Effect of High Intensity Laser on Muscle Quality and Pain in Those With Low Back Pain

University of Central Florida

Overview

The purpose of this study is to evaluate the effects of CureWave laser on paraspinal muscle oxygenation, pressure pain thresholds, muscle edema, and quality, and perceived outcomes in patients with chronic low back pain.

Low back pain (LBP) contributes to disability and has a significant economic impact. High intensity laser devices are class 4 producing \> 40 W of power at longer wavelengths, thereby allowing deeper tissue penetration. Currently, there is little evidence to demonstrate the effectiveness of high intensity laser treatment in those with chronic LBP. Optimal dosing strategies are still unknown as well as patient response based on chronicity of symptoms. Therefore, our study seeks to evaluate the effectives of high intensity laser therapy using CureWave in those with LBP of a duration longer than 3 months and with a dosing strategy of two times/week for three weeks. Hypothesis 1. CureWave laser therapy will increase total oxygenated hemoglobin and muscle blood flow in patients with chronic LBP. 2. CureWave laser therapy will reduce inflammation as assessed by muscle edema in patients with chronic LBP. 3. CureWave laser therapy will improve paraspinal echogenicity (muscle quality) following treatment in patients with chronic LBP. 4. CureWave laser therapy will decrease muscle sensitivity in patients with chronic LBP 5. CureWave laser therapy will demonstrate improve patient reported outcomes, including decreased pain, reduced disability and improved function in patients with chronic LBP. 6. CureWave laser therapy will increase muscle activation during maximal strength testing. 7. CureWave laser therapy will decrease performance fatigability as assessed by maximal muscle activation and force production.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Low Back Pain

Interventions

CureWave High Intensity LaserDEVICE

* The participant will lie prone and the HILT will be administered in 9 symmetrical positions which cover the lumbosacral region. Dose will be 1minute per position. The dose will include: * Power (44 Watts) * Mode (continues wave) * Time on (60000 ms) * Time off (1 ms) * Repeats (9) * Distance of electrode from skin will begin 10" from skin surface. The participant may or may not feel mild warmth. Should the subject report excessive warmth or discomfort the probe distance will be increased in 2" intervals until it is comfortable. The entire process will take approximately 10 minutes. * The participant will lie prone and the Placebo treatment will consist of positioning the HILT probe over the 9 symmetrical positions for 1 minutes each however the no laser will be admitted.

PlaceboOTHER

The participant will lie prone and the NON ACTIVE HILT will be administered in 9 symmetrical positions which cover the lumbosacral region. Dose will be 1minute per position. THE LASER WILL NOT BE ACTIVE. o Distance of electrode from skin will begin 10" from skin surface. The entire process will take approximately 10 minutes.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18-65 * Self-reported history of low back pain (5 episodes in lifetime or 3 in last three years which altered activities of daily living)13 Exclusion Criteria: * Self-reported pregnancy * Inability to complete all required meeting sessions * Known cardiovascular, pulmonary, metabolic, muscular, and/or coronary heart disease * Regularly uses prescription medication * Seeking medical care for the current episode of low back pain * Report average symptoms greater than 8/10 * Inability to perceive light touch. * Verbal reports of known cardiovascular, pulmonary, metabolic, muscular, and/or coronary heart disease * Verbal reports of known skin sensitivity to gels or adhesives.

Outcomes

Primary Outcomes

CHANGE in EMG activity of the lumbar paraspinal muscles

EMG will be recorded during all submaximal and maximal strength testing. EMG will be assessed using wireless Bluetooth electrodes that will be attached using double-sided adhesive stickers. All submaximal and maximal strength testing will be performed using a hand-held dynamometer (Microfet 2 Manual Muscle Tester). Subjects will be stabilized using a nylon strap, the same material and mechanism as a seat belt, when necessary to eliminate accessory or compensatory motion during strength testing. This will be placed on their anterior and/or medial thigh with padding to eliminate any discomfort where the strap contacts the skin.

Time frame: Baseline; 24-48 hours after baseline; 4 weeks after baseline

CHANGE in total hemoglobin

Change in total hemoglobin will be used as an index of change in regional blood volume.will be assessed using near-infrared spectroscopy (NIRS) (Portamon, Artinis Medical Systems, Arnhem, The Netherlands).

Time frame: Baseline; 24-48 hours after baseline; 4 weeks after baseline

CHANGE in Muscle Edema

Muscle edema will be assessed via ultrasound using the echo intensity function. Ultrasound images will be obtained using a portable brightness mode (B-mode) ultrasound-imaging device (GE Logiqe, USA) and a multi-frequency linear-array probe (12L-Rs; 5-13MHz; 38.4 mm field-of-view). Ultrasound images will be analyzed using ImageJ software (Version 1.47v., National Institutes of Health, Bethesda, MD, USA). Echo intensity, as assessed by gray-scale analysis (0 arbitrary units \[AU\], corresponds to black image, 255 AU corresponds to white image) will be performed using the histogram function and will be determined from the same region of interest as muscle thickness.

Time frame: Baseline; 24-48 hours after baseline; 4 weeks after baseline

CHANGE in Muscle sensitivity

Muscle sensitivity will be measured with a handheld digital algometer (Wagner FDX-25 pressure algometer- Wagner Instruments, Greenwich, CT) and be applied at a right angle to the skin surface with the subject lying in prone position at 3 locations on the Paravertebral muscles, Quadratus lumborum, and Piriformis. Pressure will be applied at a rate of 30 kPa/s, which corresponds to 3 N/s.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

CHANGE in Oswestry Disability Index

Measure self reported perceived disability via a standardized survey form that can report a raw score between 0 and 50 points.

Time frame: Baseline; 24-48 hours after baseline; 4 weeks after baseline

CHANGE in Patients Specific Functional Scale

Measure self reported functional abilities based on a survey form which identifies 5 individual functional tasks that the participant struggles with. These are rated 0 (no difficulty) to 10 (unable to perform task).

Time frame: Baseline; 24-48 hours after baseline; 4 weeks after baseline

CHANGE in Global Rating of Change

Measure overall change in condition via a survey questionnaire which rates change in symptoms between -7 (quite a bit worse) to 0 (no change) to +7 (quite a bit better).

Time frame: Baseline; 24-48 hours after baseline; 4 weeks after baseline

CHANGE in Sleep disturbance (short form 8a)

Measure self reported measures of sleep quality via a survey questionnaire that evaluates quality and quantity of sleep.

Time frame: Baseline; 24-48 hours after baseline; 4 weeks after baseline

CHANGE in International Physical Activity Questionnaire (IPAQ)

Measure of self reported physical activity via a survey questionnaire that reports level of physical activity.

Time frame: Baseline; 24-48 hours after baseline; 4 weeks after baseline

CHANGE in McGill Pain Questionnaire

Measure of pain quality via a survey questionnaire the measures qualitative aspects of perceived pain.

Time frame: Baseline; 24-48 hours after baseline; 4 weeks after baseline